选择性ET_A受体拮抗剂安贝生坦对急性肺栓塞小鼠的保护作用  

Protective effect of selective ET_A-receptor antagonist Ambrisentan to mice with acute pulmonary embolism

作　　者：李捷[1] 唐健[2] 颜玲娣[3] 

机构地区：[1]解放军总医院胸外科,北京100853 [2]解放军总医院第一附属医院胸心外科,北京100048 [3]军事医学科学院毒物药物研究所,北京100850

出　　处：《临床肺科杂志》2013年第11期1941-1943,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨ET A受体拮抗剂对急性肺动脉栓塞小鼠的保护作用。方法将160只小鼠分随机分为两组,一组用胶原+肾上腺素(collagen+epinephrine)制备小鼠急性肺栓塞模型(胶原组80只),另一组用凝血酶(thrombin)制备小鼠肺栓塞模型(凝血酶组80只)。每组又均分为4个亚组,在制备栓塞模型前30 min,用0.9%生理盐水和不同剂量的安贝生坦(1 mg/kg、5 mg/kg、20 mg/kg)对不同亚组的小鼠灌胃,观察急性肺栓塞小鼠的存活时间、死亡率、肺系数及肺组织病理改变情况。结果随着ETA受体选择性拮抗剂安贝生坦剂量的增加,肺动脉栓塞小鼠模型的存活时间逐渐延长,死亡率明显下降且肺系数逐渐减小;急性肺栓塞模型小鼠肺病理表现为肺动脉内多处血栓,肺泡壁和间质增厚,可见白细胞浸润和炎性渗出液。结论 ETA受体选择性拮抗剂对肺栓塞小鼠有保护作用,延长栓塞后小鼠的存活时间,降低肺栓塞引起的死亡率。Objective To discuss the protective effect of ETA-receptor antagonist Ambrisentan to mice with acute pulmonary embolism. Methods 160 mice were randomly and evenly divided into two groups. The group A was treated with collagen plus epinephrine to make pulmonary embolism model of mice, and the group B was given thrombin to make pulmonary embolism model of mice. Then each group was divided into 4 subgroups. All mice＇s stomach was douched with 0. 9% normal saline and different doses of Ambrisentan （ 1 mg/ kg, 5 mg/kg, 20 mg/kg）. The survival time, death rate, lung coefficient and the pathological changes of lung tissue of mice were ob- served. Results As the dosage of ETA-receptor antagonist Ambrisentan increased, the survival time of pulmonary embolism model of mice extended, and the mortality and lung coefficient of mice decreased. The pulmonary pathology of pulmonary embolism model of mice showed as multiple thrombus in pulmonary, alveolar walls and interstices thickened, and visible leukocyte infiltration and inflammatory exudation. Conclusion ETA-receptor antagonist has protection effect to mouse which suffers from acute pulmonary embolism. It can extend the survival time of mouse after embolism, and decrease the mortality caused by pulmonary embolism.

关 键 词：急性肺栓塞 小鼠 ETA受体拮抗剂 

分 类 号：R563.5[医药卫生—呼吸系统]